PURPOSE: Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities. Targeted TBI using helical tomotherapy results in reduced doses to normal organs, which predicts for reduced toxicities compared with standard TBI. METHODS AND MATERIALS: Thirteen patients with multiple myeloma were treated in an autologous tandem transplantation Phase I trial with high-dose melphalan, followed 6 weeks later by total-marrow irradiation (TMI) to skeletal bone. Dose levels were 10, 12, 14, and 16 Gy at 2 Gy daily/twice daily. In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan. RESULTS: For the 13 patients in the tandem autologous HCT trial, median age was 54 years (range, 42-66 years). Median organ doses were 15-65% that of the gross target volume dose. Primarily Grades 1-2 acute toxicities were observed. Six patients reported no vomiting; 9 patients, no mucositis; 6 patients, no fatigue; and 8 patients, no diarrhea. For the 8 patients in the allogeneic HCT trial, median age was 52 years (range, 24-61 years). Grades 2-3 nausea, vomiting, mucositis, and diarrhea were observed. In both trials, no Grade 4 nonhematologic toxicity was observed, and all patients underwent successful engraftment. CONCLUSIONS: This study shows that TMI using helical tomotherapy is clinically feasible. The reduced acute toxicities observed compare favorably with those seen with standard TBI. Initial results are encouraging and warrant further evaluation as a method to dose escalate with acceptable toxicity or to offer TBI-containing regimens to patients unable to tolerate standard approaches.
PURPOSE: Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities. Targeted TBI using helical tomotherapy results in reduced doses to normal organs, which predicts for reduced toxicities compared with standard TBI. METHODS AND MATERIALS: Thirteen patients with multiple myeloma were treated in an autologous tandem transplantation Phase I trial with high-dose melphalan, followed 6 weeks later by total-marrow irradiation (TMI) to skeletal bone. Dose levels were 10, 12, 14, and 16 Gy at 2 Gy daily/twice daily. In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan. RESULTS: For the 13 patients in the tandem autologous HCT trial, median age was 54 years (range, 42-66 years). Median organ doses were 15-65% that of the gross target volume dose. Primarily Grades 1-2 acute toxicities were observed. Six patients reported no vomiting; 9 patients, no mucositis; 6 patients, no fatigue; and 8 patients, no diarrhea. For the 8 patients in the allogeneic HCT trial, median age was 52 years (range, 24-61 years). Grades 2-3 nausea, vomiting, mucositis, and diarrhea were observed. In both trials, no Grade 4 nonhematologic toxicity was observed, and all patients underwent successful engraftment. CONCLUSIONS: This study shows that TMI using helical tomotherapy is clinically feasible. The reduced acute toxicities observed compare favorably with those seen with standard TBI. Initial results are encouraging and warrant further evaluation as a method to dose escalate with acceptable toxicity or to offer TBI-containing regimens to patients unable to tolerate standard approaches.
Authors: T R Mackie; J Balog; K Ruchala; D Shepard; S Aldridge; E Fitchard; P Reckwerdt; G Olivera; T McNutt; M Mehta Journal: Semin Radiat Oncol Date: 1999-01 Impact factor: 5.934
Authors: R A Clift; C D Buckner; F R Appelbaum; E Bryant; S I Bearman; F B Petersen; L D Fisher; C Anasetti; P Beatty; W I Bensinger Journal: Blood Date: 1991-04-15 Impact factor: 22.113
Authors: S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas Journal: J Clin Oncol Date: 1988-10 Impact factor: 44.544
Authors: Renata E Zaucha; Dean C Buckner; Todd Barnett; Leona A Holmberg; Ted Gooley; Heather A Hooper; David G Maloney; Frederick Appelbaum; William I Bensinger Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-19 Impact factor: 7.038
Authors: O Ringdén; T Ruutu; M Remberger; J Nikoskelainen; L Volin; L Vindeløv; T Parkkali; S Lenhoff; B Sallerfors; P Ljungman Journal: Blood Date: 1994-05-01 Impact factor: 22.113
Authors: K E Dusenbery; K A Daniels; J S McClure; P B McGlave; N K Ramsay; B R Blazar; J P Neglia; J H Kersey; W G Woods Journal: Int J Radiat Oncol Biol Phys Date: 1995-01-01 Impact factor: 7.038
Authors: R S Weiner; M M Bortin; R P Gale; E Gluckman; H E Kay; H J Kolb; A J Hartz; A A Rimm Journal: Ann Intern Med Date: 1986-02 Impact factor: 25.391
Authors: Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Jeffrey Y C Wong; Stephen Forman; George Somlo; Joseph Rosenthal; An Liu; Timothy Schultheiss; Eric Radany; Joycelynne Palmer; Anthony Stein Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-15 Impact factor: 7.038
Authors: Yutaka Takahashi; Michael R Verneris; Kathryn E Dusenbery; Christopher T Wilke; Guy Storme; Daniel J Weisdorf; Susanta K Hui Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-05 Impact factor: 7.038
Authors: George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y C Wong Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: N V N Madhusudhana Sresty; Deleep Gudipudi; A Krishnam Raju; T Anil Kumar; V R P Lakshmi; G Srikanth; M Narasimha Journal: Strahlenther Onkol Date: 2021-04-14 Impact factor: 3.621